Valeant withdraws its bid for ISTA Pharmaceuticals
TORONTO (Reuters) - Valeant Pharmaceuticals International (VRX.N: Quote) (VRX.TO: Quote) withdrew its sweetened takeover bid for ISTA Pharmaceuticals Inc ISTA.O on Monday, citing a lack of progress in talks.
ISTA said it would continue reviewing its options, and repeated that a number of parties have expressed interest in a strategic transaction.
"We were not interested in participating in a lengthy evaluation process and we are disappointed that the ISTA team was not willing to fully explore our proposal by January 31," Valeant Chief Executive Michael Pearson said in a statement.
California-based ISTA rejected Valeant's original $314 million bid in December, calling it grossly inadequate. Earlier this month, Valeant raised its bid to $7.50 from $6.50 a share in cash, and indicated it could offer up to $8.50 a share, subject to due diligence.
The drugmaker's offer was set to expire on January 31.
ISTA's shares plummeted in 2011 as sales of one of its key eye treatments for inflammation and pain were hurt by the launch of a generic version by Mylan Inc MYL.N. The stock was down 1.4 percent at $7.85 early on Monday, while Valeant stock fell 0.8 percent to C$48.79.
"While we continue to make excellent progress and are pleased with the level of interest generated to date, it will take time to complete a thorough and thoughtful review," said ISTA Chief Executive Vicente Anido.
Valeant has been active on the acquisition trail. Last year it agreed to acquire Australia's iNova Pharmaceuticals from private equity firms Archer Capital and Ironbridge for A$625 million, and it recently completed the C$88 million acquisition of Canadian cold and flu medicine maker Afexa Life Sciences.
"We continue to be disciplined on our M&A strategy and we are actively working on other opportunities that we believe can create value for our shareholders," said Pearson.
($1 = 1.0016 Canadian dollars)
(Reporting By Euan Rocha and Allison Martell; editing by Janet Guttsman)
© Thomson Reuters 2017 All rights reserved.